Navigation

Lilly drug slows Alzheimer's progression by 35% in trial

Lilly drug slows Alzheimer's progression by 35% in trial
An experimental Alzheimer's drug developed by Eli Lilly slowed cognitive decline by 35% in a closely watched late-stage trial, the company said, raising hopes for another treatment for the brain disorder that slowly destroys memory.


Share

Excelsio Media

EXCELSIO Media, is an independent source of news and information.

Post A Comment:

0 comments:

Leave a comment. Thanks!